Cited by 3,848Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel, Walde, David, Wolff, Robert A., Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy·2007·Journal of Clinical Oncology

DOI 10.1200/jco.2006.07.9525

Open this paper in CoChat — free account

Abstract

Purpose: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. Patients and Methods: Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival. Results: A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2. Conclusion: To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.9525

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H. G., Fernández‐Cruz, L., Dervenis, C., LACAINE, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,709
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citation
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Louvet, C., Labianca, R., Hammel, P. R., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M. P., Aitini, E., Taı̈eb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 948
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
Cutsem, E. V., de Velde, H. J. V., Karásek, P., Oettle, H., Vervenne, W. L., Szawlowski, A. W., Schöffski, P., Post, S., Verslype, C., Neumann, H.-J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 784
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
Berlin, J. D., Catalano, P. J., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 728
Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate
Lima, C. M. R., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 587
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
Bramhall, S. R., Schulz, J., Nemunaitis, J. J., Brown, P. D. N., Baillet, M., & BUCKELS, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Bruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 498
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Perez-Soler, R., & Saltz, L. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 485
Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial
Xiong, H. Q., Rosenberg, A., LoBuglio, A. F., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M. N., & Abbruzzese, J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.040 · Cited by 479
Self-citation
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Kindler, H. L., Friberg, G. R., Singh, D. A., Locker, G. Y., Nattam, S. R., Kozloff, M. F., Taber, D. A., Karrison, T. G., Dachman, A. H., Stadler, W. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9661 · Cited by 460
Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data
Mantel, N., & Byar, D. P. (1974) · Journal of the American Statistical Association · doi:10.1080/01621459.1974.10480131 · Cited by 446
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7010 · Cited by 311
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
Oettle, H., Richards, D., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., Zimmermann, A. H., John, W. J., Hoff, D. V., Arning, M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi309 · Cited by 305
Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer
Abou‐Alfa, G. K., Letourneau, R., Harker, W. G., Modiano, M., Hurwitz, H. I., Tchekmedyian, N. S., Feit, K., Ackerman, J., Jager, R. L. D., Eckhardt, S. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0201 · Cited by 281
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7022 · Cited by 281
Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma
Kindler, H. L., Karrison, T. G., Gandara, D. R., Lu, C. S., Krug, L. M., Stevenson, J. P., Janne, P. A., Quinn, D. I., Koczywas, M., Brahmer, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5869 · Cited by 257
The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness
Ueda, S., Ogata, S., Tsuda, H., Kawarabayashi, N., 木村, 幹., Sugiura, Y., Tamai, S., Matsubara, O., Hatsuse, K., & Mochizuki, H. (2004) · Pancreas · doi:10.1097/00006676-200407000-00061 · Cited by 246
The epidermal growth factor receptor in human pancreatic cancer
Lemoine, N. R., Hughes, C. M., Barton, C. M., Poulsom, R., Jeffery, R. E., Klöppel, G., Hall, P. A., & Gullick, W. J. (1992) · The Journal of Pathology · doi:10.1002/path.1711660103 · Cited by 205
Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis
Tobita, K., Kijima, H., Dowaki, S., Kashiwagi, H., Ohtani, Y., Oida, Y., Yamazaki, H., Nakamura, M., Ueyama, Y., Tanaka, M. R., et al. (2003) · International Journal of Molecular Medicine · doi:10.3892/ijmm.11.3.305 · Cited by 204
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
Fjällskog, M.-L. H., Lejonklou, M. H., Öberg, K. E., Eriksson, B. K., & Janson, E. T. (2003) · PubMed · Cited by 189
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Tan, A. R., Yang, X., Hewitt, S. M., Berman, A. W., Lepper, E. R., Sparreboom, A., Parr, A. L., Figg, W. D., Chow, C., Steinberg, S. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.189 · Cited by 176
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng, S. S. W., Tsao, M., Nicklee, T., & Hedley, D. W. (2002) · PubMed · Cited by 164
Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201)
Poplin, E. A., Levy, D. E., Berlin, J., Rothenberg, M. L., O'Dwyer, P. J., Cella, D. F., Mitchell, E. P., Alberts, S. R., & Benson, A. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.lba4004 · Cited by 125
Molecular targeting therapy for pancreatic cancer
Xiong, H. Q. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0890-2 · Cited by 89
Controlled Study of Fatigue, Quality of Life, and Somatic and Mental Morbidity in Epithelial Ovarian Cancer Survivors: How Lucky Are the Lucky Ones?
Liavaag, A. H., Dørum, A., Fosså, S. D., Trope, C. G., & Dahl, A. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1769 · Cited by 75
A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer
Richards, D., Kindler, H. L., Oettle, H., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., John, W. J., Arning, M., & Hoff, D. D. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4007 · Cited by 74
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)
O'Reilly, E. M., Abou-Alfa, G. K., Letourneau, R., Harker, W. G., Modiano, M., Hurwitz, H. I., Tchekmedyian, N. S., Ackerman, J., Jager, R. L. D., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4006 · Cited by 73
Interstitial Lung Disease in Lung Cancer
Danson, S. J., Blackhall, F. H., Hulse, P. A., & Ranson, M. (2005) · Drug Safety · doi:10.2165/00002018-200528020-00002 · Cited by 62
GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma : final results of the GERCOR /GISCAD Intergroup Phase III
Louvet, C., Labianca, R., Hammel, P. R., Lledo, G., de Braud, F., André, T., Cantore, M., Ducreux, M. P., Zaniboni, A., & de Gramont, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4008 · Cited by 61
A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer
Neuhaus, P., Oettle, H., Post, S., Gellert, K., Ridwelski, K., Schramm, H., Zülke, C., Fahlke, G., Langrehr, J. M., & Riess, H. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4013 · Cited by 58
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy
Gilliam, A. D., & Watson, S. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.397 · Cited by 38
In Reply:
Newlands, E. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.242 · Cited by 29
Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21
Tsao, M., Sakurada, A., Lorimer, I. A. J., Cutz, J.-C., Kamel‐Reid, S., Squire, J. A., Ding, K., Frank, R., Seymour, L., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7007 · Cited by 17
Self-citation
Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy
Szucs, T. D., Léonard, R., Pettengell, R., Paridaens, R., Jackisch, C., Constenla, M., Bosly, A., & Schwenkglenks, M. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.619 · Cited by 13
Laparoscopic radiofrequency ablation and systemic chemotherapy for colorectal liver metastases
McCain, D. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3776 · Cited by 13
Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects
Karyekar, C. S., Carr, R. A., Andre, A., Wang, Q., Facey, I., Marsh, K. G., Daszkowski, D. J., & Humerickhouse, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3080 · Cited by 10
Optimized phase I-II trial design for vaccination with epidermal growth factor (EGF): Effect on immunogenicity and safety
Neninger, E., Gonzalez, G., Crombet, T., Fleites, G., Leonard, I., Gonzalez, M., Badia, T., & Lage, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2610 · Cited by 6

Flagged first, then by citations

1 of the 49 references couldn’t be matched to a known paper.

Sorted by citations

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citation
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Pancreatic cancer
Vincent, A., Herman, J. M., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,678

See all 3,848

Authors: Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W.
Affiliations: Norton Healthcare (US)
From the Divisions of Medical Oncology, Hematology, and Surgical Oncology, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Kingston; Algoma District Cancer Program, Sault Ste Marie, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; the Australasian Gastrointestinal Tumor Group, Sydney, Australia; Norton Healthcare Pavilion, Louisville, KY; UCLA Medical Center, Los Angeles, CA; M. D. Anderson Cancer Centre, Houston, TX; OSI Pharmaceuticals, Boulder...
ORCID: Moore, Malcolm J.
Goldstein, David
Hamm, John
Hecht, Joel R.
Au, Heather J.
Wolff, Robert A.
Ding, Keyue
Clark, Gary
Parulekar, Wendy
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2007-05-20
Volume: 25
Issue: 15
Pages: 1960-1966
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2006.07.9525
OpenAlex: W2158134441
Cited by: 3,848
References: 49
Citations by year: 2026: 45 · 2025: 62 · 2024: 123 · 2023: 113 · 2022: 129 · 2021: 178 · 2020: 159 · 2019: 170 · 2018: 204 · 2017: 217 · 2016: 242 · 2015: 275 · 2014: 274 · 2013: 251 · 2012: 268
FWCI: 133.78
Type: journal article
Language: en
Update notices: new_edition (2023-10-17)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: erlotinib, gemcitabine, advanced pancreatic cancer, targeted therapy, overall survival, progression-free survival, metastatic pancreatic cancer, combination chemotherapy, adverse events
MeSH terms: Erlotinib Hydrochloride, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Double-Blind Method, Female, Humans, International Agencies, Male, Middle Aged, Pancreatic Neoplasms, Placebos, Prognosis, Quinazolines, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks